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Bone metastasis occurs in the majority of patients with late-stage breast and prostate cancers and is often diagnosed in lung, thyroid, bladder, and kidney cancers. Bone 
metastasis is associated with characteristic modulation of the bone microenvironment, resulting in the formation of a “metastatic niche” that can form before or upon the arrival 
of disseminated tumor cells to facilitate seeding and expansion of tumor colonies in bone. Tumor cells condition the metastatic niche through the secretion of soluble factors, 
such as PTHrP, HPSE, and OPN. Circulating PTHrP induces CCL2 production from osteoblasts and other bone stromal cells, which in turn stimulates VEGF expression in the 
tumor cells and enhances angiogenesis, while tumor-supplied HPSE increases osteoclast activity and bone resorption. OPN facilitates αVβ3-mediated adhesion and migra-
tion of tumor cells and recruits bone marrow cells, promoting the growth of indolent tumors. Bone-tropic carcinomas express factors that aid in recruitment and seeding to the 
bone. Tumor cells preferentially adhere to bone marrow endothelial cells and are further localized to the bone through interactions between tumor-expressed integrins and their 
ligands. Specifically, αVβ3 binding to vitronectin and OPN and α4β1 integrin binding to VCAM-1 and fibronectin are essential for tumor colonization. Similarly, tumor-expressed 
CXCR4 binds to osteoblast-produced CXCL12, resulting in tumor cell occupancy of the hematopoietic stem cell (HSC) niche and a decrease in HSC self-renewal. Other factors 
are commonly upregulated during cancer cells seeding in the bone, including IL-11, CTGF, MMP1, and HIF-1α. HIF-1α is elevated in tumor cells due to the hypoxic conditions 
found in the bone, resulting in increased expression of VEGF and CXCR4. Decreased expression of IRF7 in metastatic tumor cells helps to accelerate bone metastasis seeding 
and growth through the suppression of NK and T cell immune responses.
Osteolytic and Osteoblastic Metastasis
Osteolytic metastases (predominant in breast cancer metastasis) are mediated by interactions of tumor cells with osteoblasts and osteoclasts and involve aberrant bone resorp-
tion due to the recruitment and activation of osteoclasts to the tumor-bone interface. In addition to secreting elevated levels of osteoclast differentiation factor RANKL, tumor 
cells also produce PTHrP and IL-6 to activate RANKL secretion from osteoblasts. Additionally, secreted matrix metalloproteases (MMPs) play an important role in osteolysis; 
MMP7 cleaves and activates RANKL, whereas MMP1 decreases levels of OPG, the decoy receptor and inhibitor of RANKL. Activated osteoblasts at the metastatic lesion also 
secrete CSF-1/MCSF, initiating osteoclast differentiation from monocyte precursors, followed by further induction via RANKL. Osteoclast differentiation is enhanced by the 
binding of tumor-expressed Jagged1 to Notch receptors on pre-osteoclasts, and osteoclast differentiation and activity are amplified by tumor-secreted MIP-1α, IL-6, IL-8, and 
GM-CSF.
Osteoblastic lesions (predominant in prostate cancer) involve imbalanced bone homeostasis that leads to increased osteoblast differentiation and activity and results in 
uncontrolled bone formation. Tumor-secreted WNT is central to osteoblast differentiation during bone metastasis, activating multiple downstream genes, including the essential 
transcription factor RUNX2. DKK1, a secreted inhibitor of WNT, is highly expressed in osteolytic metastasis but is suppressed by PTHrP in late-stage prostate cancers, enforcing 
the osteoblastic lesions. Bone metastases stimulate osteoblast activity through the secretion of additional factors, including BMPs, IGFs, FGF, and Endothelin-1. Tumor cells also 
secrete factors that indirectly influence osteoblast activity, including VEGF, which can regulate osteoclasts and induce angiogenesis, and PSA, which can degrade PTHrP and 
decrease osteolysis. In addition to improper bone formation, osteoblastic lesions often feature aberrant osteolysis due to osteoblast-secreted RANKL.
Vicious Cycle
The dysregulated bone development during bone metastasis results in the release of factors from stromal cells and the bone microenvironment, many of which positively regulate 
tumor growth, leading to a vicious cycle. TGFβ, IGF, and Ca2+ are released from the bone matrix during lysis, enhancing tumor proliferation and survival. TGFβ signaling in tumor 
cells enhances expression of bone metastasis proteins PTHrP, Jagged1, CTGF, IL-11, and MMPs. Calcium signaling through the calcium-sensing receptor leads to increased 
proliferation and survival. Osteoblasts also secrete a number of proteins that positively regulate tumor growth, including IL-6, SPARC, and periostin. SPARC induces cancer 
migration and homing through the αVβ5 integrin, whereas Periostin and IL-6 promote tumor survival.
Interactions with Other Bone Stromal Cells
Other stromal cells interact with metastatic cells, including neurons, platelets, and bone marrow endothelial cells. Sympathetic neuron activation by bone metastasis results 
in severe pain, as well as increased tumor proliferation and colonization. Tumor cells preferentially bind to bone marrow endothelial cells and activate platelet aggregation, 
inducing angiogenesis and increasing tumor survival and proliferation. Tumor cells also influence mesenchymal stem cell differentiation into osteoblast and other mesenchymal 
lineages.
Dormancy and Outgrowth of Disseminated Tumor Cells in Bone
The presence of disseminated tumor cells (DTCs) in the bone marrow is an indicator of poor prognosis. DTCs occupy the HSC niche, displacing HSCs and maintaining a dormant 
state. Survival of dormant cells is enhanced through expression of Twist1, as well as Src signaling that enhances tumor response to CXCL12 and decreases TRAIL-mediated 
apoptosis. Increased VCAM-1 expression in dormant tumor cells can recruit osteoclast precursors expressing α4β1 integrin, leading to the induction of osteolysis.
Treatment Options
Osteoclasts are a prominent therapeutic target. FDA-approved treatments include bisphosphonates, direct inhibitors of osteoclasts, as well as the anti-RANKL antibody deno-
sumab. Other therapeutics in stage II or stage III trials include inhibitors of Cathepsin K (an osteoclast-secreted protease), Src, and TGFβ. In addition, osteoblasts are targeted 
by inhibitors of Endothelin1 in osteoblastic metastases.
RefeRences
Bidwell, B.N., Slaney, C.Y., Withana, N.P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N.E., Samarajiwa, S.A., et al. (2012). Silencing of Irf7 pathways in breast 
cancer cells promotes bone metastasis through immune escape. Nat. Med.
Campbell, J.P., Karolak, M.R., Ma, Y., Perrien, D.S., Masood-Campbell, S.K., Penner, N.L., Munoz, S.A., Zijlstra, A., Yang, X., Sterling, J.A., and Elefteriou, F. (2012). Stimulation of host 
bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol. 10, e1001363.
Clézardin, P. (2011). Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res. 13, 207.
Lacey, D.L., Boyle, W.J., Simonet, W.S., Kostenuik, P.J., Dougall, W.C., Sullivan, J.K., San Martin, J., and Dansey, R. (2012). Bench to bedside: elucidation of the OPG-RANK-RANKL 
pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419.
Logothetis, C.J., and Lin, S.H. (2005). Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5, 21–28.
Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., Yan, J., Hua, Y., Tiede, B.J., Lu, X., et al. (2011). VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of 
breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 20, 701–714.
Mundy, G.R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593.
Schneider, J.G., Amend, S.R., and Weilbaecher, K.N. (2011). Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 48, 54–65.
Shiozawa, Y., Pedersen, E.A., Havens, A.M., Jung, Y., Mishra, A., Joseph, J., Kim, J.K., Patel, L.R., Ying, C., Ziegler, A.M., et al. (2011). Human prostate cancer metastases target the 
hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298–1312.
Weilbaecher, K.N., Guise, T.A., and McCauley, L.K. (2011). Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411–425.
